DE60138404D1 - Verbessertes system zur regulation der transgenexpression - Google Patents

Verbessertes system zur regulation der transgenexpression

Info

Publication number
DE60138404D1
DE60138404D1 DE60138404T DE60138404T DE60138404D1 DE 60138404 D1 DE60138404 D1 DE 60138404D1 DE 60138404 T DE60138404 T DE 60138404T DE 60138404 T DE60138404 T DE 60138404T DE 60138404 D1 DE60138404 D1 DE 60138404D1
Authority
DE
Germany
Prior art keywords
transgenexpression
regulating
improved system
inducer
inducibility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138404T
Other languages
English (en)
Inventor
Ronald V Abruzzese
Vidya Mehta
Jeffrey L Nordstrom
Jason G Fewell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Genetronics Inc
Original Assignee
Baylor College of Medicine
Genetronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Genetronics Inc filed Critical Baylor College of Medicine
Application granted granted Critical
Publication of DE60138404D1 publication Critical patent/DE60138404D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Paper (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mushroom Cultivation (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Eye Examination Apparatus (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60138404T 2000-09-25 2001-09-25 Verbessertes system zur regulation der transgenexpression Expired - Lifetime DE60138404D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23503000P 2000-09-25 2000-09-25
US26078101P 2001-01-10 2001-01-10
US27828101P 2001-03-23 2001-03-23
PCT/US2001/030305 WO2002024899A2 (en) 2000-09-25 2001-09-25 Improved system for regulation of transgene expression

Publications (1)

Publication Number Publication Date
DE60138404D1 true DE60138404D1 (de) 2009-05-28

Family

ID=27398677

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138404T Expired - Lifetime DE60138404D1 (de) 2000-09-25 2001-09-25 Verbessertes system zur regulation der transgenexpression

Country Status (7)

Country Link
US (1) US7579326B2 (de)
EP (1) EP1326969B1 (de)
AT (1) ATE428790T1 (de)
AU (1) AU2001296354A1 (de)
CA (1) CA2423093C (de)
DE (1) DE60138404D1 (de)
WO (1) WO2002024899A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401327C (en) * 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
US9453219B2 (en) * 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
WO2006037215A1 (en) * 2004-10-04 2006-04-13 National Research Council Of Canada Expression system, components thereof and methods of use
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
US20060292609A1 (en) * 2005-05-19 2006-12-28 Schering Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
EP1885858A2 (de) * 2005-05-19 2008-02-13 Bayer Schering Pharma Aktiengesellschaft Behandlung von krankheiten unter anwendung eines verbesserten regulierten expressionssystems
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
WO2007134907A2 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
WO2007134906A1 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
KR101803099B1 (ko) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
ES2525411T3 (es) * 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
MX340972B (es) * 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
US9746475B2 (en) 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
EP3868387A1 (de) 2012-07-20 2021-08-25 Taiga Biotechnologies, Inc. Verbesserte wiederherstellung und autorenkonstitution des hämatopoietischen abteils
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
AU2016282879A1 (en) * 2015-06-26 2018-01-18 Bayer Animal Health Gmbh Methods of modulating cytosolic DNA surveillance molecules
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US20170198363A1 (en) * 2015-12-28 2017-07-13 Colorado State University Research Foundation Compositions and methods for detection of small molecules
WO2017134137A1 (en) * 2016-02-05 2017-08-10 Polygene Ag Glucocorticoid-based gene regulation system
EP3235516B1 (de) 2016-04-22 2019-06-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Regulierbarer adeno-assoziierter virus (aav)-vektor
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
WO2018102678A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11780902B1 (en) 2018-07-20 2023-10-10 Colorado State University Research Foundation Receptor/histidine kinase fusion constructs and uses thereof
WO2021173647A1 (en) * 2020-02-25 2021-09-02 University Of Massachusetts Inducible single aav system and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS62171696A (ja) 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
AU633045B2 (en) 1988-12-23 1993-01-21 Salk Institute For Biological Studies, The Receptor transcription-repression activity compositions and methods
CA2057049A1 (en) 1989-05-26 1990-11-27 Ronald M. Evans Dominant negative members of the steroid/thyroid superfamily of receptors
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US6416998B1 (en) * 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
AU685054C (en) * 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
HUT73876A (en) 1993-04-29 1996-10-28 Abbott Lab Erythropoietin analog compositions and methods
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
ATE371736T1 (de) * 1996-10-29 2007-09-15 Baylor College Medicine Modifizierte steroid-hormon rezeptoren
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
GB9718591D0 (en) * 1997-09-03 1997-11-05 Zeneca Ltd Methods
KR20010040309A (ko) * 1997-12-23 2001-05-15 스티븐 에이. 서윈. 엠.디. 여러 개의 아데노수반 바이러스 벡터를 사용하여 다수의유전자를 세포 내로 전달하는 방법
GB9817660D0 (en) 1998-08-13 1998-10-07 Angeletti P Ist Richerche Bio Adenoviral vectors encoding erythropoietin and their use in gene therapy
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
WO2000031286A1 (en) * 1998-11-20 2000-06-02 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
CA2401327C (en) * 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use

Also Published As

Publication number Publication date
US20030220286A1 (en) 2003-11-27
ATE428790T1 (de) 2009-05-15
CA2423093C (en) 2013-09-17
WO2002024899A2 (en) 2002-03-28
EP1326969A2 (de) 2003-07-16
EP1326969B1 (de) 2009-04-15
CA2423093A1 (en) 2002-03-28
WO2002024899A3 (en) 2002-12-12
AU2001296354A1 (en) 2002-04-02
US7579326B2 (en) 2009-08-25

Similar Documents

Publication Publication Date Title
DE60138404D1 (de) Verbessertes system zur regulation der transgenexpression
DE602005015994D1 (de) siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
EA199900162A1 (ru) Ингибиторы клеточной адгезии
ATE430589T1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
ATE395826T1 (de) Verwendung von 3-(2,4,6-trimethylphenyl)-4- neopentylcarbonyloxy-5,5-tetramethylen- dihydrofuran-2-on zur bekämpfung von psylliden
ATE408624T1 (de) Verfahren zur reinigung von fsh
DK1562444T3 (da) Fremgangsmåde til formindskelse af acrylamidindholdet i varmebehandlede levnedsmidler
DE60330376D1 (de) Defructosylierungsverfahren
ATE390125T1 (de) Formulierung für einen dosierinhalator unter verwendung von hydro-fluoro-alkanen als treibstoffe
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
ATE446314T1 (de) Methode zur reinigung von fsh
CA2429679A1 (en) Hd3a gene inducing flowering of plant and utilization thereof
DE50210608D1 (de) Vorrichtung zur kontrolle von material
ATE543502T1 (de) Allomon-abstossungsmittel zur kontrolle von arachnidae
ATE364087T1 (de) Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
DK1210446T3 (da) Modificeret ubiquitin-regulatorisk system
FR2827169B1 (fr) Durcisseur pour les ongles
DE50008241D1 (de) Metallschaumkörper auf basis von zink
ATE273394T1 (de) Wirts-vektor-systeme zur phosphatregulierten überproduktion von polypeptiden in bacillus
ATE437846T1 (de) Cyclooct-(en-)yl-derivate zur verwendung als duftstoffe
TW200700130A (en) Message character string output system and controlling method of the same and information memory media
ATE335087T1 (de) Globaler regulator, verwendet zur erhöhung der synthese von aromatischen substanzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition